Study Population | Seropositive CMV-IgM (%) | Equivocal | |
| Positive | Negative |
|
Recipients (n = 40) | 9 (22.5%) | 29 (72.5%) | 2 (5%) |
Use of CMV Prophylaxis | |||
| Acyclovir | Ganciclovir | No Prophylaxis |
Recipients (n = 40) | 15 (37.5%) | 1 (2.5%) | 24 (60%) |
Immunosuppressive Regimen | Number of Recipients (%) | ||
| n = 40 | ||
CPA | 14 (35%) | ||
CPM | 22 (55%) | ||
Others* | 4 (10%) | ||
Acute rejection episodes |
| ||
Yes | 20 (50%) | ||
No | 20 (50%) |